Genetics and epigenetics of renal cell cancer

Biochimica Et Biophysica Acta
Marcella M L BaldewijnsManon van Engeland

Abstract

Renal cell carcinoma (RCC) is not a single disease, but comprises a group of tumors of renal epithelial origin, each with a different histology, displaying a different clinical course and caused by different genetic alterations. Since cure rates are inversely associated with stage and response to the available treatment regimes is limited to a subgroup of patients, diagnostic methods facilitating early detection and new therapeutic modalities are necessary. Increased knowledge of the underlying pathophysiology of RCC has resulted in the identification of genetic alterations involved in renal cell cancer carcinogenesis. Promising agents to target these pathways, especially the angiogenesis pathway, are being developed, some of which are already standard of care. In addition to genetics, knowledge on epigenetics in the process of renal tumorigenesis has been significantly increased in the last decades. Epigenetics will play an increasing role in the development of new therapeutic modalities and may deliver new prognostic and early diagnostic markers. In this review we discuss the background of RCC and the clinical applications of RCC genetics and epigenetics.

References

Dec 1, 1977·Archives of Dermatology·A R BirtW J Dubé
Oct 31, 1992·International Journal of Cancer. Journal International Du Cancer·J K McLaughlinJ F Fraumeni
Apr 1, 1991·Urology·R Washecka, M Hanna
May 1, 1991·American Journal of Clinical Pathology·T MuradK Bauer
Apr 1, 1991·British Journal of Urology·J F BrennanM B Siroky
Nov 1, 1990·Epidemiology·M Maclure, W Willett
May 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·M HorioI Pastan
Feb 1, 1987·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H B MussM S Mitchell
Aug 1, 1986·The Journal of Urology·J D Maldazys, J B deKernion
Dec 1, 1982·American Journal of Clinical Oncology·M M OkenP P Carbone
Oct 1, 1982·The American Journal of Surgical Pathology·S A FuhrmanC Limas
Oct 9, 1995·International Journal of Cancer. Journal International Du Cancer·J K McLaughlinH O Adami
Sep 1, 1995·The Journal of Urology·T B CrottyM M Lieber
Jan 27, 1995·International Journal of Cancer. Journal International Du Cancer·M McCredieS Niwa
May 1, 1994·Nature Genetics·J R GnarraF M Duh
Oct 11, 1994·Proceedings of the National Academy of Sciences of the United States of America·J G HermanW M Linehan
Nov 15, 1994·International Journal of Cancer. Journal International Du Cancer·W H ChowJ S Mandel
Dec 1, 1993·Journal of the American Academy of Dermatology·J S RothM E Grossman
Mar 1, 1994·The Journal of Urology·B ZbarW M Linehan
Aug 19, 1993·International Journal of Cancer. Journal International Du Cancer·S BenhamouR Flamant
Mar 1, 1993·Cancer Causes & Control : CCC·N KreigerG A Darlington
Jan 1, 1996·Cancer Causes & Control : CCC·A WolkH O Adami
May 1, 1997·Molecular Medicine Today·P W Laird
Dec 9, 1997·The Journal of Pathology·G KovacsB Zbar
Jul 22, 1998·Proceedings of the National Academy of Sciences of the United States of America·A SchoenfeldR D Burk
Sep 30, 1998·Proceedings of the National Academy of Sciences of the United States of America·O IliopoulosW G Kaelin
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T CangianoA Belldegrun
Mar 20, 1999·American Journal of Epidemiology·J A ShapiroW E Barlow
May 26, 1999·Journal of the National Cancer Institute·H BrauchT Brüning

❮ Previous
Next ❯

Citations

Dec 27, 2011·Cancer Letters·Carmen Jerónimo, Rui Henrique
Jun 12, 2012·Nature Genetics·Samuel Peña-LlopisJames Brugarolas
Jul 31, 2008·Journal of the National Cancer Institute·Jinliang XingXifeng Wu
Jun 8, 2012·Science Translational Medicine·Sharanya SivanandJames Brugarolas
May 29, 2012·Molecular Cancer Research : MCR·Eric JonaschW Kimryn Rathmell
Oct 28, 2009·Journal of Translational Medicine·Barbara SeligerReinhard Dammann
Nov 10, 2013·PloS One·Ilsiya IbragimovaPaul Cairns
Aug 5, 2009·Internal Medicine·Naoko SekizawaYukio Hirata
Nov 30, 2013·Medical Oncology·Wei-Jie MaJun Zhang
Aug 7, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Yongqing GaoGaobo Yan
Nov 2, 2014·Proceedings of the National Academy of Sciences of the United States of America·Shan-Shan WangJames Brugarolas
Mar 4, 2014·FEBS Letters·Claire M Robinson, Michael Ohh
Jun 20, 2013·Science China. Life Sciences·Yi GaoLiang Zhao
Sep 6, 2012·International Journal of Cancer. Journal International Du Cancer·Rafal PawłowskiPeter Schraml
Jul 31, 2013·Journal of Cellular and Molecular Medicine·Patrícia PatrícioCarmen Jeronimo
Jan 1, 2010·The American Journal of Pathology·Iris J H van VlodropManon van Engeland
Dec 20, 2014·European Journal of Clinical Investigation·Márcia Vieira-CoimbraCarmen Jerónimo
May 7, 2015·BioMed Research International·Garima SharmaJu-Suk Nam
Mar 15, 2012·Epigenetics : Official Journal of the DNA Methylation Society·Julia LiepKlaus Jung
Mar 16, 2012·Epigenetics : Official Journal of the DNA Methylation Society·Faranaz AtschekzeiJürgen Serth
Feb 20, 2017·Experimental and Molecular Pathology·Claudia CorròMarkus Rechsteiner
May 19, 2010·Biomarkers in Medicine·Hirendra Nath Banerjee, Mukesh Verma
Mar 22, 2019·Biotechnic & Histochemistry : Official Publication of the Biological Stain Commission·T KuloğluS Aydin
May 16, 2019·Epigenetics : Official Journal of the DNA Methylation Society·Qianying ZhuSu Zeng
Nov 25, 2014·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Ying-Li LinJian-Guo Ma
Jun 25, 2016·Nutrition and Cancer·Leo J SchoutenManon van Engeland
May 14, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James Brugarolas
Mar 24, 2020·Pharmaceutical Biology·Lili DaiPeizheng Lin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Cancer Epigenetics Chromatin Complexes (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin complexes and their role in cancer epigenetics.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

Cancer Epigenetics and Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Cancer Epigenetics and Chromatin (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin and its role in cancer epigenetics please follow this feed to learn more.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.